Takahashi, Masayuki http://orcid.org/0000-0003-2449-3148
Daizumoto, Kei
Fukawa, Tomoya
Fukuhara, Yayoi
Bando, Yoshimi
Kowada, Minoru
Dondoo, Tsogt-Ochir
Sasaki, Yutaro
Tomida, Ryotaro
Ueno, Yoshiteru
Tsuda, Megumi
Kusuhara, Yoshito
Yamaguchi, Kunihisa
Yamamoto, Yasuyo
Uehara, Hisanori
Kanayama, Hiroomi
Funding for this research was provided by:
NOVARTIS Foundation (Japan) for the Promotion of Science (NOVARTIS Foundation (NA)
Merck & Co., Inc. | MSD K.K. (NA)
Article History
Received: 11 August 2020
Revised: 27 May 2023
Accepted: 13 June 2023
First Online: 24 June 2023
Competing interests
: M Takahashi received honoraria from Pfizer Inc. and a research grant from Novartis Pharma and MSD. HK received honoraria from Pfizer Inc. Other authors have no conflict of interest.
: The study was approved by the ethical review board of Tokushima University Hospital (permission number 709) and conducted according to the ethical standards of the Declaration of Helsinki. The ethical review board of Tokushima University Hospital (permission number: 1841) and the Institutional Animal Care and Use Committee (Permission number: T2019-56) of Tokushima University approved the animal experiments. All of the animal experiments were performed according to guidelines of the animal facility at the University of Tokushima and conform to Fundamental Guidelines for Proper Conduct of Animal Experiments and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology in Japan.
: Written informed consent for data usage and publication was obtained from all patients.